Monty Rakusen Background In business since 1954 as a division of Eli Lilly (LLY), Elanco Animal Health (NYSE:EL.AN) was spun off as an independent public company in 2018. In the animal health space, Elanco is second by revenue, behind leader Zoetis (ZTS), with roughly half the revenue of Zoctis, Zoetis was spun off from Pfizer in 2012. Jeffrey N. Simmons has been President and CEO of Elanco since the spinoff from Eli Lilly. On August 1, 2020, Elanco purchased Bayer Animal Health in a deal valued at $6.99 bi ...

NEW YORK, Aug. 16, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Elanco Animal Health Incorporated (NYSE:ELAN) for potential violations of the federal securities laws. If you invested in Elanco, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/elanco-animal-health-incorporated. Why Did Elanco's Stock Drop? Elanco develops products to treat diseases in animals. Two of the most importan ...

Study finds that the aggressive lone star tick is no match for Credelio GREENFIELD, Ind., Aug. 15, 2024 /PRNewswire/ -- Parasites & Vectors, a leading peer-reviewed journal focused on parasites and vector-borne pathogens published the results of a head-to-head study demonstrating that Credelio, a prescription flea and tick protection product from Elanco Animal Health, has the fastest initial speed of tick kill in just 12 hours and sustains that advantage throughout the dosing interval.1,2,3 According to the ...

NEW YORK, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Elanco Animal Health Incorporated (NYSE:ELAN) for potential violations of the federal securities laws. If you invested in Elanco, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/elanco-animal-health-incorporated. Why Did Elanco's Stock Drop? Elanco develops products to treat diseases in animals. Two of the most importan ...

NEW YORK, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Elanco Animal Health Incorporated (NYSE:ELAN) for potential violations of the federal securities laws. If you invested in Elanco, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/elanco-animal-health-incorporated. Why Did Elanco's Stock Drop? Elanco develops products to treat diseases in animals. Two of the most importan ...

NEW YORK, Aug. 10, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Elanco Animal Health Incorporated (NYSE:ELAN) for potential violations of the federal securities laws. If you invested in Elanco, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/elanco-animal-health-incorporated. Why Did Elanco's Stock Drop? Elanco develops products to treat diseases in animals. Two of the most importan ...

财务数据和关键指标变化 - 公司第二季度收入为11.84亿美元,同比增长12%,剔除汇率影响后增长13% [34] - 价格贡献了4%的增长 [34] - 宠物健康业务第二季度常汇率收入增长13%,其中美国业务增长1% [35] - 农场动物业务全球收入增长14%,美国业务增长17% [39][40] 各条业务线数据和关键指标变化 - 美国宠物健康业务受零售客户采购模式变化影响,但终端消费者需求保持良好 [14][36][37] - 国际宠物健康业务增长11%,主要受益于主要品牌如Seresto和Credelio Plus的强劲表现 [16] - 国际农场动物业务保持平稳,其中家禽和牛业务表现强劲,抵消了亚洲猪业的下滑 [17][18] 各个市场数据和关键指标变化 - 美国农场动物业务增长17%,主要受益于Experior、Rumensin和疫苗供应的改善 [18][19] - 国际农场动物业务中,家禽和牛业务占比接近3/4,增长势头良好 [17] - 猪业务作为公司最小的业务板块,受到供给过剩和养殖利润下降的压力 [18] 公司战略和发展方向及行业竞争 - 公司正在执行创新、产品组合和生产效率提升的三大战略 [7][20][21] - 公司将在未来3个季度推出3款潜在的新产品,进一步丰富产品线 [8][23][24][30] - 公司正在加强与客户的合作,提升产品价值主张,提高市场份额 [20] - 公司正在优化生产流程,提高现金流,并通过出售水产业务偿还了13亿美元债务 [21] 管理层对经营环境和未来前景的评论 - 公司对全年业绩保持信心,预计全年有机收入增长3%-4% [10] - 管理层对Zenrelia和Credelio Quattro等新产品的上市前景表示乐观 [13][26][30][31] - 管理层认为Bovaer产品在奶牛养殖行业有广阔的市场前景 [24][25] 其他重要信息 - 公司发布了2023年ESG报告,展示了在内部运营、客户合作等方面的可持续发展进展 [11] - 公司预计到2024年底净负债率将降至中4倍水平,2025年将进一步降至低4倍至高3倍 [45] 问答环节重要的提问和回答 问题1 **Jon Block 提问** 关于Zenrelia产品的头对头数据和疫苗反应研究的问题 [55][56] **Jeffrey Simmons 回答** 公司将在产品获批后的投资者电话会议上分享Zenrelia的标签信息、差异化优势以及上市策略 [57][58][59][60][61] 问题2 **Michael Ryskin 提问** Zenrelia的定价策略和产品组合带来的协同效应 [67] **Jeffrey Simmons 回答** 公司将采取基于价值的定价策略,并利用产品组合的协同效应来推动Zenrelia的市场渗透 [68][69][73] 问题3 **Umer Raffat 提问** 关于Zenrelia产品标签中的安全警示信息的更多细节 [75] **Jeffrey Simmons 回答** 公司将在获批后详细解释Zenrelia标签信息,并通过教育培训等方式帮助兽医理解和正确使用该产品 [77][78]

Elanco Animal Health Incorporated (ELAN) reported $1.18 billion in revenue for the quarter ended June 2024, representing a year-over-year increase of 12%. EPS of $0.30 for the same period compares to $0.18 a year ago. The reported revenue represents a surprise of +3.23% over the Zacks Consensus Estimate of $1.15 billion. With the consensus EPS estimate being $0.24, the EPS surprise was +25.00%. While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expec ...

业务表现 - 公司产品在全球90多个国家销售，约54%的收入来自外币[93] - 2024年第二季度收入为11.84亿美元，同比增长12%[93] - 宠物健康业务收入为5.79亿美元，同比增长12%[93] - 农场动物业务收入为5.94亿美元，同比增长13%[93] - 2024年上半年收入为23.89亿美元，同比增长3%[95] - 宠物健康业务收入为12.18亿美元，同比增长2%[95] - 农场动物业务收入为11.5亿美元，同比增长5%[95] - 公司营收总额为11.84亿美元，同比增长12%[98] - 宠物健康业务营收为5.79亿美元，同比增长12%[98] - 农场动物业务营收为5.94亿美元，同比增长13%[98] - 合同制造业务营收为1100万美元，同比下降8%[98] - 宠物健康业务6个月营收为12.18亿美元，同比增长2%[100] - 农场动物业务6个月营收为11.5亿美元，同比增长5%[100] 重组与出售 - 2023年4月公司与拜耳动物保健业务整合导致部分收入从2023年第二季度转移到第一季度[93] - 公司预计将于2024年第三季度完成出售水产业务并预计获得6.3亿至6.6亿美元的税前收益[88] - 公司于2024年2月启动重组计划以提高运营效率，预计将产生3000万至3500万美元的年度净节省[89] 成本费用 - 成本费用方面，销售成本占营收比例从40%上升至42%[103][104] - 研发费用同比增加9%至1.76亿美元[105] - 销售及管理费用同比增加2%至6.91亿美元[107][108] - 资产减值及重组费用同比增加68%至1.26亿美元[112][113] 流动性与现金流 - 公司主要流动性来源为现金、经营活动现金流和信贷额度[119] - 公司持有大部分现金在美国境外，会根据预计现金流需求调整境外现金[119] - 截至2024年6月30日，公司现金及现金等价物为4.16亿美元，未使用的循环信贷额度约为7.5亿美元[119] - 2024年7月3日，公司修订了循环信贷额度，延长至2029年7月[119] - 出售水务业务后，公司使用12.22亿美元现金偿还了定期贷款，大幅降低了负债和未来利息支出[119] - 2024年上半年经营活动产生的现金流为2.02亿美元，较2023年同期增加2.86亿美元[120,121] - 2024年上半年投资活动产生的现金流为0.4亿美元，较2023年同期增加1.02亿美元[121,122] - 2024年上半年筹资活动产生的现金流为-1.2亿美元，较2023年同期减少3.33亿美元[122] - 公司认为现有流动性资金足以满足短期和长期资本需求[119]

Elanco Animal Health Incorporated (ELAN) came out with quarterly earnings of $0.30 per share, beating the Zacks Consensus Estimate of $0.24 per share. This compares to earnings of $0.18 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 25%. A quarter ago, it was expected that this company would post earnings of $0.26 per share when it actually produced earnings of $0.34, delivering a surprise of 30.77%. Over the last four quart ...